KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Gilead Sciences (GILD) over the last 11 years, with Q3 2025 value amounting to $3.8 billion.

  • Gilead Sciences' Other Accumulated Expenses fell 2336.6% to $3.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 billion, marking a year-over-year decrease of 2336.6%. This contributed to the annual value of $5.5 billion for FY2024, which is 651.07% up from last year.
  • Latest data reveals that Gilead Sciences reported Other Accumulated Expenses of $3.8 billion as of Q3 2025, which was down 2336.6% from $3.6 billion recorded in Q2 2025.
  • Gilead Sciences' 5-year Other Accumulated Expenses high stood at $6.1 billion for Q4 2021, and its period low was $3.6 billion during Q2 2025.
  • Its 5-year average for Other Accumulated Expenses is $4.8 billion, with a median of $4.6 billion in 2025.
  • Per our database at Business Quant, Gilead Sciences' Other Accumulated Expenses surged by 16869.26% in 2021 and then plummeted by 2546.79% in 2022.
  • Quarter analysis of 5 years shows Gilead Sciences' Other Accumulated Expenses stood at $6.1 billion in 2021, then fell by 25.47% to $4.6 billion in 2022, then increased by 12.01% to $5.1 billion in 2023, then increased by 6.51% to $5.5 billion in 2024, then tumbled by 31.33% to $3.8 billion in 2025.
  • Its Other Accumulated Expenses was $3.8 billion in Q3 2025, compared to $3.6 billion in Q2 2025 and $4.6 billion in Q1 2025.